Sugammadex facilitates early recovery after surgery even in the absence of neuromuscular monitoring in patients undergoing laryngeal microsurgery: a single-center retrospective study

Table 1 Demographic and clinical data of patients

Variables	Group S (n = 68)	Group P (n = 67)
Age (years)	51.8 ± 12.9	52.9 ± 12.0
Sex (M/F)	45/23	46/21
Height (cm)	165.3 ± 8.2	165.3 ± 8.8
Weight (kg)	66.6 ± 12.2	66.9 ± 12.1
ASA class (I/II)	29/39	23/44
Operation type (Biopsy/Resection)	10/58	10/57
Induction propofol/thiopental dose (mg kg⁻¹)	1.9 ± 0.2 / 4.7 ± 0.3	1.84 ± 0.26 / 4.77 ± 0.48
Operation time (min)	9.6 ± 6.0	10.0 ± 7.0
Insp. SEVO/DES (vol %) at the end of surgery	2.15 ± 0.55 / 6.16 ± 0.68	2.35 ± 0.6 / 6.04 ± 1.06

The patient data are presented as mean ± SD or number of patients. There was no statistically significant difference between the groups for any of the variables. Group S: patients who received sugammadex as a reversal agent. Group P: patients who received pyridostigmine as a reversal agent
M male, F female, ASA American Society of Anaesthesiologists, Insp. Inspiratory, SEVO Sevoflurane, DES Desflurane

ISSN: 1471-2253